Unlock instant, AI-driven research and patent intelligence for your innovation.

Antibody of TrkA and application thereof

A technology of antibodies and antigens, applied in applications, antibodies, anti-inflammatory agents, etc., can solve problems such as frequent administration, poor patient compliance, and short half-life of small molecule drugs

Active Publication Date: 2020-12-01
SUNSHINE LAKE PHARM CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Small-molecule TrkA kinase inhibitors are more problematic
First of all, the half-life of small molecule drugs is generally short, the administration is frequent, and the patient's compliance is poor
Secondly, small-molecule Trka kinase inhibitors are receptor tyrosine kinase inhibitors. There are many receptor tyrosine kinases in the body. Therefore, it is difficult to guarantee the specificity and selectivity of drugs for specific targets. Many reactions, high toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody of TrkA and application thereof
  • Antibody of TrkA and application thereof
  • Antibody of TrkA and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0260] Embodiment 1 hybridoma technology screening anti-TrkA monoclonal antibody

[0261] Hybridoma cell lines that can produce anti-TrkA monoclonal antibodies that block the combination of NGF and TrkA at the molecular level were screened by hybridoma technology and ELISA. The NCBI database was used to design the gene encoding the extracellular region of TrkA protein, which was constructed into a mammalian eukaryotic expression system, and the extracellular region of TrkA protein was expressed for screening of anti-TrkA monoclonal antibodies. The extracellular region of the immunogen TrkA protein was obtained from Beijing Yiqiao Shenzhou Biotechnology Co., Ltd. After Balb / C mice were immunized by intraperitoneal injection three times, the serum antibody titer of the immunized mice was determined by ELISA method and reached 10 5 class. After booster immunization, the spleen was fused with myeloma cells. Use HAT selection medium and HT selection medium to selectively culture ...

Embodiment 2

[0262] Example 2 HEK-293T-TrkA cell model screening anti-TrkA monoclonal antibody

[0263]The HEK-293T-TrkA cell model was constructed by lentivirus technology, and the hybridoma cell line that could produce anti-TrkA monoclonal antibody that blocked the binding of NGF and TrkA at the cellular level was screened by flow cytometry. Biotinylate NGF, use NGF to bind to the extracellular region of TrkA protein on HEK-293T-TrkA cells, anti-TrkA monoclonal antibody can also bind to the extracellular region of TrkA protein on HEK-293T-TrkA cells, design competition experiments , by flow cytometry, detect the combination of NGF and the extracellular region of TrkA protein on HEK-293T-TrkA cells under the action of anti-TrkA monoclonal antibody, and screen the anti-TrkA monoclonal antibody that blocks the binding of NGF and TrkA at the cellular level. After screening, a total of 9 monoclonal hybridoma cell lines that can produce anti-TrkA monoclonal antibodies that block the binding of...

Embodiment 3

[0264] Example 3 Application of ELISA method to detect positive clones to produce human-mouse cross-reaction of monoclonal antibodies

[0265] The binding of the monoclonal antibody produced by the supernatant of each positive clone to the Mouse-TrKA receptor was detected by ELISA method, and the human-mouse cross-reaction of the monoclonal antibody produced by the positive clone was detected. The results are shown in image 3 , in the figure, OD 450 The value reflects the binding strength of the antibody to the protein, and the larger the reading value, the stronger the binding of the antibody to the protein. As shown in the figure, the OD of 23E12, 21E5, 15D4, 27H3 groups 450 The value is around 3.5, which is significantly different from the negative control group; OD of 20C8, 1B9, 4H4, 3A5, 22D12 groups 450 The value is almost close to 0, and there is no significant difference compared with the negative clone group. It can be seen that clones 23E12, 21E5, 15D4, and 27H3 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an antibody or an antigen binding fragment thereof capable of specifically recognizing TrkA and application hereof. The antibody contains a CDR sequence selected from at least one of the following sequences or an amino acid sequence having at least 95% identity therewith: a heavy chain variable region CDR sequence: SEQ ID NO: 1-27, and a light chain variable region CDR sequence: SEQ IN NO: 28-54. According to the embodiment of the invention, the antibody can be specifically combined with a TrkA receptor in a targeting manner to block the combination of NGF and TrkA.

Description

technical field [0001] The present invention relates to the field of biotechnology. Specifically, the present invention relates to TrkA antibodies and applications thereof. More specifically, the present invention relates to antibodies capable of specifically recognizing TrkA or antigen-binding fragments thereof, nucleic acid molecules, expression vectors, recombinant cells, and drugs. Composition, pharmaceutical use, kit for detecting TrkA and mouse B cells. Background technique [0002] Currently, for mild to moderate pain, non-opioid analgesics, such as nonsteroidal anti-inflammatory drugs (NSAIDs), are mainly used clinically; for moderate to severe pain, opioid analgesics are mainly used. However, NSAIDs have a "capping effect", opioids can only effectively relieve less than 30% of non-tumor chronic pain, and 20% of cancer pain patients have opioid drug resistance. In addition, NSAIDs have gastrointestinal and cardiovascular safety hazards, especially during long-term m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13G01N33/573C12N5/10A61K39/395A61P29/00A61P35/00A61P25/28A61P15/00A61P25/02A61P3/10A61P13/08A61P19/08A61P37/02A61P11/00A61P13/10A61P1/00A61P17/00A61P17/02A61P9/00A61P13/12A61P19/02A61P27/02A61P35/02
CPCA61P29/00A61P35/00A61P25/28A61P15/00A61P25/02A61P13/08A61P35/02C07K2317/565C07K2317/92A61K2039/505C07K16/2863A61P25/04A61P13/00G01N33/6893G01N33/57484G01N33/74C07K2317/56C07K2317/51C07K2317/515C07K2317/52C07K2317/33C07K2317/76A61P1/00A61P3/10A61P9/00A61P11/00A61P13/10A61P13/12A61P19/02A61P19/08A61P17/00A61P17/02A61P27/02A61P37/02G01N2333/48G01N2800/2842C07K2317/30C07K2317/24C07K2317/622
Inventor 陈超任志衡何转娣卢杰联林树珊于婷婷危喜玲王旭昉徐乐董军纪李想张阔杨雪尧郭林峰李晓平陈小锋李文佳
Owner SUNSHINE LAKE PHARM CO LTD